(Q35579525)

9 August 2017

1 reference

title

Targeting thrombin--rational drug design from natural mechanisms (English)

1 reference

9 August 2017

Targeting thrombin – rational drug design from natural mechanisms (English)

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

30 March 2024

author name string

James A. Huntington

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607082

30 March 2024

Trevor P. Baglin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607082

30 March 2024

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0165614703002852?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

https://api.elsevier.com/content/article/PII:S0165614703002852?httpAccept=text/plain

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Trends in Pharmacological Sciences

30 March 2024

published in

1 reference

9 August 2017

volume

24

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

589-595

1 reference

Thrombin activity of fibrin thrombi and soluble plasmic derivatives

9 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II

30 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin

30 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The molecular basis of thrombin allostery revealed by a 1.8 A structure of the "slow" form

30 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The clot thickens: clues provided by thrombin structure.

30 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex

30 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface

30 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Molecular mapping of the heparin-binding exosite of thrombin

30 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Structure of the Ser195Ala mutant of human alpha--thrombin complexed with fibrinopeptide A(7--16): evidence for residual catalytic activity

30 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Molecular mapping of thrombin-receptor interactions

30 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes

30 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease

30 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments

30 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Structural requirements for the activation of human factor VIII by thrombin

30 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII

30 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains

30 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity

30 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism

30 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C.

30 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

30 March 2024

ART-123 Asahi Kasei

26

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Mechanisms of glycosaminoglycan activation of the serpins in hemostasis

30 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The anticoagulant activation of antithrombin by heparin

30 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement

30 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.

30 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The role of heparin cofactor II in the modulation of hemostasis

30 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The molecular genetics of familial venous thrombosis

30 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Complete antithrombin deficiency in mice results in embryonic lethality

30 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Heparin cofactor II inhibits arterial thrombosis after endothelial injury

30 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

30 March 2024

Heparin cofactor II.

38

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Low-molecular-weight heparins

30 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Heparin-induced thrombocytopenia: an overview

30 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Heparin‐induced thrombocytopenia: pathogenesis and management

30 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

30 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin

30 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes.

30 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Orgaran (Org 10172): its pharmacological profile in experimental models

30 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Vasoflux, a new anticoagulant with a novel mechanism of action

30 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)

30 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase

30 March 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Pharmacological activity of a low molecular weight dermatan sulfate (desmin) in healthy volunteers

30 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.

30 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Synthesis of thrombin-inhibiting heparin mimetics without side effects

30 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Inhibition of fibrin-bound thrombin by a covalent antithrombin-heparin complex

30 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Development of direct thrombin inhibitors in comparison with glycosaminoglycans

30 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Refined structure of the hirudin-thrombin complex

30 March 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor

30 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug

30 March 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

From natural to synthetic multisite thrombin inhibitors

30 March 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Hirudin as alternative anticoagulant--a historical review

30 March 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Kinetics of the inhibition of thrombin by hirudin.

30 March 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Leech thrombin inhibitors

30 March 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

30 March 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence

30 March 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

The role of Glu(192) in the allosteric control of the S(2)' and S(3)' subsites of thrombin

30 March 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis

30 March 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Oral delivery of new heparin derivatives in rats

30 March 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies

30 March 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.TIPS.2003.09.002

30 March 2024

Identifiers

1 reference

9 August 2017

1 reference